Sildenafil Pediatric Dosing (Under 12): What Clinicians and Parents Need to Know

This draft is pending qualified clinical review. It is not a substitute for individualized medical advice, and no dosing decision for a specific child should be made from this page alone.

The direct answer

Sildenafil is not indicated, studied, or appropriate for erectile dysfunction in children under 12; that use exists only in adult men under the Viagra label. In pediatric pulmonary arterial hypertension, the FDA's current position (last clarified in March 2014) is that low, weight-banded doses of Revatio may be used in children ages 1 to 17, while doses above the labeled range should be avoided because of a mortality signal identified in extension follow-up of the pivotal pediatric trial program. The clinically important question for a child already on sildenafil is not simply "does it work," but whether the prescribed dose sits inside or outside that FDA-defined low-dose boundary, because the safety concern that reshaped this drug's pediatric use was specific to dose level, not to the underlying decision to treat.

Entity check: which drug, which brand, which indication

Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor. The same molecule is marketed as Viagra for erectile dysfunction in adult men and as Revatio for pulmonary arterial hypertension in adults and, under specific conditions, in children. A child's medication list showing "sildenafil" or "Revatio" almost always reflects PAH treatment, not a sexual health use. Confusing the two indications matters clinically: the ED dosing, patient population, and safety monitoring have nothing in common with pediatric PAH dosing.

Why some children under 12 are prescribed sildenafil

Sildenafil inhibits PDE5, an enzyme that breaks down cyclic GMP in pulmonary vascular smooth muscle. In pulmonary arterial hypertension, elevated pulmonary artery pressure strains the right ventricle; pulmonary vasodilation can lower that pressure and, in principle, improve exercise tolerance and right heart function. Pediatric PAH is rare and historically carried substantial mortality before targeted therapies became available. Sildenafil was one of the first PDE5 inhibitors studied specifically in children with PAH, in a multinational randomized, placebo-controlled trial program often referred to by its "STARTS" trial names in the pulmonary hypertension literature.

Note on sourcing: the original trial reports (STARTS-1 and its open-label extension, STARTS-2) are widely cited in pediatric cardiology literature, but the specific identifiers referenced in earlier versions of this article could not be independently verified for this revision. The description below is deliberately general. Anyone using this information clinically should pull the primary trial publications directly rather than relying on a secondhand citation.

What the trial program is understood to show, and what needs verification

Based on how the FDA's own safety communications describe the underlying evidence:

• An initial randomized, dose-ranging trial in treatment-naive children with PAH tested low, medium, and high oral sildenafil doses against placebo over about 16 weeks and found evidence of improved pulmonary hemodynamics across dose groups.
• An open-label extension of that trial, with several years of follow-up, reported a dose-dependent increase in mortality, with more deaths in children who had received higher doses.
• This mortality finding, not the underlying decision to treat pediatric PAH, is what changed regulatory guidance.

Specific figures such as exact patient counts, exact hazard ratios, or exact percentage mortality differences appear in secondary sources but are not reproduced here because they could not be verified against a confirmed primary citation for this revision. A clinician relying on precise numeric risk estimates should retrieve the original trial publication and the FDA review documents rather than any number that cannot be traced to a specific, checked source.

What the FDA has said, and when

• On August 30, 2012, the FDA issued a Drug Safety Communication recommending against use of Revatio (sildenafil) in children ages 1 to 17 with PAH, based on the mortality signal described above (an FDA drug safety communication issued in 2012). That communication was broadly worded, and it was widely interpreted at the time as discouraging pediatric sildenafil use in general.
• In March 2014, the FDA clarified that low doses of sildenafil may be appropriate for children with PAH, while doses above the labeled range should not be used (a subsequent FDA clarification issued in 2014). The Revatio label was updated with the current weight-based pediatric dosing and the mortality warning.

Both communications are dated regulatory actions; a clinician or parent checking current status should confirm there has been no subsequent label update, since drug safety communications can be superseded.

A quotation attributed to an FDA official in earlier versions of this article could not be verified against a checkable primary source and has been removed rather than repeated inaccurately. The substance of the FDA's clarified position, that low-dose pediatric use is not prohibited but high-dose use should be avoided, is retained because it is supported directly by the 2014 communication above.

Weight-based dosing as currently labeled

According to the FDA's 2014 clarification and the current Revatio label for pediatric PAH:

Children weighing 8 kg to 20 kg: 10 mg orally three times daily.

Children weighing more than 20 kg: 20 mg orally three times daily.

This is the low-dose regimen the FDA considers acceptable; doses above these weight bands are the ones associated with the mortality signal and should not be used outside a specialist center managing an individual child's risk-benefit tradeoff. The oral suspension (10 mg/mL) allows accurate low-volume dosing for small children; splitting tablets to approximate a 10 mg dose introduces avoidable dosing error and should be avoided when suspension is available.

For infants under 1 year, there is no FDA-approved pediatric dose. Use in neonates, discussed below, is off-label and should be considered investigational rather than standard care.

Neonatal use (PPHN): off-label, and distinct from the PAH indication

Persistent pulmonary hypertension of the newborn (PPHN) is a separate, acute neonatal condition. Inhaled nitric oxide is the established first-line pulmonary vasodilator for PPHN. Sildenafil is used off-label in some neonatal units when inhaled nitric oxide is unavailable, when a newborn is not responding to it, or during weaning. A Cochrane systematic review of sildenafil for neonatal pulmonary hypertension has reported suggestive but limited evidence of benefit, drawn mostly from small trials with meaningful risk of bias, and has called for larger controlled trials before treating the evidence as definitive.

There is no FDA-approved neonatal dose. Reported off-label starting doses in the literature are generally in the range of 0.5 mg/kg enterally every 6 to 8 hours, titrated to hemodynamic response, but this figure comes from small pilot studies and case series rather than a regulatory label, and should not be treated as a standing prescription guide.

Monitoring, drug interactions, and discontinuation risk

Hemodynamic monitoring. Pediatric PAH management generally involves baseline assessment of pulmonary pressures (echocardiography, and right heart catheterization in specialist centers), with periodic reassessment tied to clinical trajectory rather than a fixed universal schedule.

Hepatic function. Sildenafil is metabolized hepatically. Children with hepatic impairment may reach higher plasma levels at a given dose, which is one reason liver function is typically checked at baseline and periodically during therapy.

Vision and hearing symptoms. PDE5 inhibitors have documented cross-reactivity with retinal PDE6, and adult sildenafil use has been associated with rare reports of visual disturbance and sudden hearing loss. Any new visual change, sudden vision loss, or sudden hearing loss in a child on sildenafil warrants urgent evaluation rather than watchful waiting.

Blood pressure. Sildenafil can cause systemic hypotension. Symptoms of lightheadedness, especially on standing, should be reported promptly.

Drug interactions. Nitrates are absolutely contraindicated with sildenafil because of the risk of severe hypotension; this matters if a child on sildenafil requires nitroglycerin in a surgical or emergency setting. Strong CYP3A4 inhibitors (for example, ketoconazole, clarithromycin, ritonavir) can raise sildenafil levels substantially. Bosentan, a CYP3A4 inducer commonly used alongside sildenafil in pediatric PAH, can lower sildenafil levels; combination use requires monitoring of clinical response rather than an automatic dose increase, given the dose-related mortality signal described above.

Discontinuation. Abrupt withdrawal of sildenafil in a child with PAH can precipitate rebound pulmonary hypertension, a sudden worsening of pulmonary pressures that can cause right heart failure. When discontinuation is planned, gradual tapering with monitoring, or an overlap period when switching to another PAH therapy, is the standard approach rather than stopping abruptly. Missed doses from any cause (illness, travel, pharmacy or insurance disruption) carry the same underlying risk as a planned but abrupt stop, and families should have a clear plan for what to do if a dose is missed rather than deciding in the moment.

Escalation when sildenafil alone is not enough

Children with an inadequate response to sildenafil monotherapy may be escalated to combination therapy: an endothelin receptor antagonist (bosentan is the most studied in children), a prostacyclin pathway agent (epoprostenol, treprostinil, or inhaled iloprost) for more advanced disease, or, in refractory cases, procedures such as atrial septostomy or evaluation for lung transplantation. These decisions belong to a pediatric pulmonary hypertension specialist team; the FDA's low-dose boundary for sildenafil itself does not change based on how advanced the disease is, so escalation happens by adding or switching therapies, not by exceeding the labeled sildenafil dose.

What is established, what is plausible, and what is not established

Established: Sildenafil has no pediatric ED indication. Sildenafil is FDA-labeled for pediatric PAH at specific weight-based low doses. The FDA has formally warned against doses above that range based on a mortality signal identified in pediatric trial follow-up. Abrupt discontinuation carries a real risk of rebound pulmonary hypertension.

Plausible but not fully settled by the evidence available here: The precise magnitude of the mortality difference between low and high pediatric doses, the exact mechanism behind the dose-related mortality signal, and the long-term survival benefit of sildenafil in the modern era of combination PAH therapy. These would need direct primary-source verification before being cited with specific numbers.

Not established: A standard, FDA-approved neonatal dosing regimen for PPHN. Sildenafil's role as anything other than off-label, investigational therapy in newborns. Any pediatric ED use of sildenafil under any circumstance.

Clinician and parent monitoring framework: label guidance versus individualized care

This framework separates what the FDA label and general guideline-level monitoring themes support from decisions that require an individual pediatric PAH specialist's judgment. It is a discussion structure, not a protocol to self-apply.

Checkpoint 1: Before starting therapy

• Confirm the indication is PAH, not any off-label extrapolation to another form of pulmonary hypertension without specialist input.
• Confirm the dose matches the weight band (8-20 kg: 10 mg TID; >20 kg: 20 mg TID) and flag any prescribed dose above this range for explicit discussion of the risk-benefit rationale.
• Baseline assessment: cardiac imaging/hemodynamic evaluation, liver function, and a documented baseline for vision and hearing.
• Label guidance ends here; individualized care begins with how aggressively to escalate if baseline disease severity is high, that decision sits with the specialist team, not the label.

Checkpoint 2: Early follow-up (weeks to a few months)

• Ask directly: is the current dose within the FDA low-dose band, and has anyone proposed exceeding it? If yes, that is a stop-and-discuss point, not a routine titration.
• Screen for new visual changes, sudden hearing changes, or symptoms of low blood pressure (dizziness, fainting, lightheadedness on standing).
• Confirm a documented plan for missed doses and for what a family should do if a dose is missed for more than one interval.

Checkpoint 3: Ongoing monitoring

• Periodic hemodynamic reassessment (echocardiography, and catheterization when clinically indicated) on a schedule set by the specialist team based on disease trajectory, not a fixed universal calendar.
• Periodic liver function testing, particularly if any new interacting medication (CYP3A4 inhibitor or inducer) is added.
• Growth and developmental tracking, since PAH itself and its treatment interact with nutritional status.

Stop-and-escalate conditions (seek urgent care):

• Sudden vision loss or sudden hearing loss.
• Fainting, severe dizziness, or symptoms suggesting profound hypotension.
• Signs of worsening right heart failure (new or worsening shortness of breath, swelling, blue-tinged lips or fingertips, marked fatigue) which could indicate either disease progression or a rebound effect from a missed dose.
• Any unplanned gap in dosing of more than a day or two in a child previously stable on therapy; this should prompt a call to the treating team, not independent dose adjustment.

Where the label stops and individualized judgment starts:

• The label sets the acceptable dose ceiling; it does not resolve when to add a second PAH-targeted agent, when to attempt a taper, or how to sequence a switch between therapies. Those are specialist-level decisions that weigh the individual child's hemodynamics, growth, and response, and they are appropriately made by a pediatric pulmonary hypertension program, not derived from this article or from the drug label alone.

Common questions